Literature DB >> 6681322

Histamine H-1 binding site on human polymorphonuclear leukocytes.

S Wescott, M Kaliner.   

Abstract

Neutrophilic polymorphonuclear leukocytes (PMN) infiltrate the sites of allergic reactions and may respond to histamine, one of the major mediators of allergy. In order to characterize histamine interactions with PMN, the binding of [3H]pyrilamine was studied. Human PMNs bind [3H]pyrilamine in a specific, saturable, and reversible fashion and demonstrate specificity (H-1 antagonists greater than histamine greater than H-2 antagonists) for the competitive binding agents studied. Human PMNs have a homogeneous population of H-1 receptors of moderate affinity (Kd = 52 nM) in large number (265 X 10(3)/cell) which do not demonstrate cooperativity. Thus PMNs attracted to sites of allergic inflammation have H-1 binding sites which may respond to histamine stimulation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6681322     DOI: 10.1007/bf00917266

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  23 in total

1.  Cold urticaria. Recognition and characterization of a neutrophil chemotactic factor which appears in serum during experimental cold challenge.

Authors:  S I Wasserman; N A Soter; D M Center; K F Austen
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

2.  Late cutaneous allergic responses in isolated IgE-dependent reactions.

Authors:  J Dolovich; F E Hargreave; R Chalmers; K J Shier; J Gauldie; J Bienenstock
Journal:  J Allergy Clin Immunol       Date:  1973-07       Impact factor: 10.793

3.  The IgE-mediated release of an eosinophil leukocyte chemotactic factor from human lung.

Authors:  A B Kay; K F Austen
Journal:  J Immunol       Date:  1971-09       Impact factor: 5.422

4.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

5.  Histologic studies of human skin test responses to ragweed, compound 48-80, and histamine.

Authors:  P Atkins; G R Green; B Zweiman
Journal:  J Allergy Clin Immunol       Date:  1973-05       Impact factor: 10.793

6.  The biologic activity of mast cell granules. III. Purification of inflammatory factors of anaphylaxis (IF-A) responsible for causing latephase reactions.

Authors:  H L Oertel; M Kaliner
Journal:  J Immunol       Date:  1981-10       Impact factor: 5.422

7.  The effects of the immunologic release of histamine upon human lung cyclic nucleotide levels and prostaglandin generation.

Authors:  L F Platshon; M Kaliner
Journal:  J Clin Invest       Date:  1978-12       Impact factor: 14.808

8.  Purification and synthesis of eosinophilotactic tetrapeptides of human lung tissue: identification as eosinophil chemotactic factor of anaphylaxis.

Authors:  E J Goetzl; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1975-10       Impact factor: 11.205

9.  The selective eosinophil chemotactic activity of histamine.

Authors:  R A Clark; J I Gallin; A P Kaplan
Journal:  J Exp Med       Date:  1975-12-01       Impact factor: 14.307

View more
  3 in total

Review 1.  Drugs and receptors. An overview of the current state of knowledge.

Authors:  T Kenakin
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

2.  The histamine H4 receptor is a potent inhibitor of adhesion-dependent degranulation in human neutrophils.

Authors:  Karim Dib; Tomas Perecko; Veronika Jenei; Cheryl McFarlane; David Comer; Vanessa Brown; Mwape Katebe; Torsten Scheithauer; Robin L Thurmond; Paul L Chazot; Madeleine Ennis
Journal:  J Leukoc Biol       Date:  2014-05-05       Impact factor: 4.962

Review 3.  Histamine in cancer immunology and immunotherapy. Current status and new perspectives.

Authors:  María de la Paz Sarasola; Mónica A Táquez Delgado; Melisa B Nicoud; Vanina A Medina
Journal:  Pharmacol Res Perspect       Date:  2021-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.